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We identified 11,602 patients receiving chemotherapy in public hospitals. During 
follow-up, 7,417 patients (63.9%) received expensive drugs at least once, including 
mostly pemetrexed (57.5%), bevacizumab (16.9%), or topotecan (7.2%); these patients 
were significantly more likely women and younger than the rest of the cohort 
(p< 0.0001). Conversely, all selected comorbidities were associated with lower rates 
of administration i.e. chronic renal failure, diabetes, hypertension, COPD and other 
respiratory diseases (p< 0.0001). Taking as reference patients from affluent areas, we 
observed lower rates of access in intermediary affluent, intermediary deprived and 
deprived areas. After multivariate adjustment, odd ratios were 0.85 [95%:0.75–0.95], 
0.82 [95%:0.74–0.92] and 0.80 [95%:0.71–0.89], respectively. ConClusions: Even in 
a health care system organized to ensure a high degree of equity in medical care, 
we found indications of a socioeconomic gradient in innovative anticancer drugs 
access in lung cancer.
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ThE Economic impAcT of An hypoThETicAl Rx-To-oTc SwiTch in SpAin
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objeCtives: Tight public budget constraints have accelerated the debate on the 
extent of prescribed medications that are publicly covered in Spain, a country with 
one of the lowest percentage of OTC sales over total drugs sales. The objective 
of this study is to examine the economic impact of payer policies consisting on 
a hypothetical Rx-to-OTC switch of 5% of currently publicly covered prescription 
drugs for mildest conditions. Methods: A decision model is used to estimate the 
economic impact of the switch. Both third-party-payer and societal perspectives 
are adopted, using a five-year timeframe, both at regional (17 regions) and national 
levels. The model is inspired by a previous ones in European countries, but the 
timeframe and the effects measured have been further developed for the sake of 
robustness and better reflection of the current Spanish reality. The effects, meas-
ured in monetary units, include those regarding to quality of primary care, labor 
productivity, the opportunity cost for non-working populations, and financial bur-
den of pharmaceutical expenditure. Resources allocated to improving responsible 
self medication are also accounted for. The study analyses the effects on different 
stakeholders (patients, NHS, and society). Finally, it includes both a standard and 
a probabilistic sensitivity analysis. Results: The switch results in a 3.125€ millon 
societal effect, explained by improving quality of primary health care (2.258M€ ), 
improving labor productivity (507), optimization of non working patients’time (579) 
and a reduction of public expenditure on publicly covered medication (979). On 
the other hand, there are negative effects from increasing privately funded drugs 
(1.165) and the cost of improving self-care (35). Sensitivity analyses confirm overall 
results (p< 0,01). ConClusions: Under increasing budgets constraints, switch-
ing drugs for mild conditions may be a solution with positive societal net effects, 
although the distribution of the impacts among stakeholders might make the ini-
tiative unpopular.
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objeCtives: Since the introduction of orphan legislation the number of orphan 
drugs has dramatically increased. The objective of the study is to compare 
orphan designations and approvals in the EU, USA and Japan. Methods: The 
list of molecules with orphan status, as well as the list of approved orphan drugs 
(ODs) in the USA, EU and Japan were identified from the websites of Food and 
Drug Administration (FDA) of the USA, the European Medicines Agency (EMA), and 
National Institute of Biomedical Innovation, Health and Nutrition. All available 
details on orphan designations and approvals were extracted. Results: By June 
2015, 3465 orphan designations were granted in the USA, 1503 in the EU and 399 
in Japan. More than 60% of orphan designations led to an approval in Japan, about 
14% in the USA, and only 7% in the EU. The median delay between granting an 
orphan designation and approval was more than three years in the USA and EU, 
and about two years in Japan. EMA publishes the most detailed information on 
orphan designations and OD approvals. Unlike the USA and Japan, the details on 
refusals in orphan status or approvals together with decision rationale are available 
in the EU. ConClusions: A higher number of ODs has been approved in the USA. 
However, many of them have been discontinued, particularly among ODs approved 
before 2000. The relatively small number of ODs approved in the EU might be related 
to the lower financial support of ODs provided in the EU compared to the USA and 
Japan. A noticeably high commercialisation rate is observed in Japan, which can be 
associated with the feasibility criteria applied to the drugs submitting for orphan 
designation on the one hand, and with the arrival on Japan market of molecules 
already commercialized in other countries on the other.
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objeCtives: The objectives are to present the scorecard HTA system used in Romania 
from July 2014 and the results in terms of access of new therapies at reimburse-
ment. Methods: The authors studied the scorecard HTA legislation and the relation-
ship with the health-care environment from the last 2 years considering: the evolution 
of the Romanian HTA methodologies, the HTA process and the implications in other 
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objeCtives: Patient registries are a good source of evidence for health-care pro-
viders, payers and regulators requiring real-world data for evidence-based deci-
sion making. This review aimed to identify and assess key characteristics of the 
heart failure (HF) registries reporting patients’ data from five European Union (EU5) 
countries. Methods: HF registries were identified through a systematic search of 
Embase and PubMed databases. Inclusion criteria were data on HF patients from 
EU5 countries (France, Germany, Italy, Spain, and the UK) and patient counts ≥ 1000. 
Registry publications and websites were assessed for availability of information on 
patient characteristics, disease management, resource use, treatment outcomes and 
funding agency. Results: Of 23 identified registries reporting data for HF patients, 
43% were multinational while 57% were national-level registries. Twelve registries 
each collected data from Spain, Germany, and Italy and eight and six registries from 
France and the UK, respectively. Data was collected for patients with acute HF only 
(31%), chronic HF only (43%), and both acute and chronic HF (26%) in the identified 
registries. Number of included patients varied from 1037 to 25,000 with the average 
follow-up ranging from 3-53 months. Data was available for patient demographics 
(in 100% registries), comorbidities (87%), diagnosis and disease classification (78%), 
mortality (78%), hospitalisation (96%), prescribed drugs (100%), and patient-reported 
outcomes (17%). Registries also collected data on specific diagnostic tools (blood 
pressure, ECG, blood tests, biomarkers, imaging, and renal function tests), treat-
ment procedures (revascularisation, catheterization, and transplant), resource use, 
adverse events, and cost. Of these registries, 65% initiated during last 10 years and 
61% were industry-funded. ConClusions: Registries are a rich source of real-
world information on HF patients which can be turned into actionable insights 
for important health-care decisions. Rise in the number of HF registries in recent 
years and industry funding indicates increased interest of stakeholders in these 
registries’ data.
EqUiTy & AccESS STUDiES
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objeCtives: In April 2014, the European Medicines Agency (EMA) announced an 
adaptive pathways pilot enabling initial approval of a medicine for a restricted 
patient population with very high unmet need based on early clinical studies. 
Progressive adaptations of the marketing authorisation would expand access to 
broader patient populations based on subsequent data. However, such an adaptive 
license may pose a problem for payer bodies, many of which currently require a 
long time period to review medicines under strict clinical and economic criteria. 
This research aims to evaluate how ready major European current payer systems 
would be to encompass EMA adaptive pathways. Methods: Key European payer 
bodies from the EU5 (NICE, SMC, HAS, IQWiG/G-BA, AIFA and AEMPS were scored by 
PAREXEL’s Commercialization panel of pricing and reimbursement experts on 4 key 
criteria: (1) speed of appraisal, (2) flexibility to clinical data appraisal approach, (3) 
flexibility to economic data appraisal approach, and (4) no additional local/regional 
access hurdles as either high (2 points), medium (1 point) or low (0 points). Results: 
Out of a possible 8 points, HAS scored the highest (7) followed by SMC (6), AIFA (5), 
AEMPS (5), IQWiG (4) with NICE the lowest (2). Low scores for NICE were driven by 
its long duration for decision-making alongside rigid adherence to ICER thresholds. 
Higher scores for SMC were based on their much faster appraisals and flexibil-
ity through the new PACE process. AIFA and AEMPS both scored moderately with 
positive flexibility in their approaches tempered by additional local/regional access 
hurdles. In Germany, rigid adherence to direct comparative trial data versus the 
relevant comparator limited positive scoring. ConClusions: some payers (most 
notably NICE) will need to make significant changes to their appraisal processes 
In order for early market approval under adaptive pathways to translate into early 
reimbursement and payer access
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objeCtives: Lung cancer survival is socioeconomically patterned, and socioeco-
nomic inequalities in receipt of treatment have been demonstrated in several coun-
tries. In the hospitals, many innovative anticancer drugs are too expensive to be 
funded through a Diagnosis-Related Group (DRG) of chemotherapy administration. 
In France, such drugs are fully reimbursed up to national reimbursement tariffs 
(extra-DRG funding) to ensure equity of access. Our aim was to analyze the access 
of patients to innovative drugs according to social deprivation index. Methods: 
A retrospective cohort study was constituted with all patients having a diagnosis 
of metastatic lung cancer in the French National hospitals databases (PMSI) during 
year 2011. Patients’ data were linked to allow a two-year follow-up period. Because 
extra-DRG data were not available for private hospitals, our analysis was restricted 
to patients benefiting from chemotherapy in public hospitals only. In addition 
of demographic characteristics, comorbidities, and treatment, we assigned each 
patient to social deprivation index based on their postcode of residence. Results: 
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objeCtives: Different jurisdictions organize their health technology assessment 
(HTA) capacity in different ways. In theory, a centralized approach offers the poten-
tial to pool the scarce resources devoted to HTA and national recommendations can 
be issued to encourage a uniform development of services across the whole country. 
On the other hand, a regional approach could help in tailoring recommendations to 
local needs. The objective of this study was to compare the assessment procedures 
in England (centralized approach) with Spain (regional approach). Methods: We 
compared the assessments of the same cancer drugs in the two jurisdictions from 
2000 to 2015, extracting data on the availability of an HTA, the indication(s) studied, 
the comparator(s) considered, the cost-effectiveness assessments produced and the 
reimbursement recommendation (recommended with no restrictions, optimized 
or denied use). Results: The indications studied and the comparators considered 
were similar in the two jurisdictions. In England an HTA with a cost-effectiveness 
estimate was available for 105 drug/indication pairings: recommended (32%), opti-
mized(30%) and denied(38%). The Spanish HTA for pharmaceuticals is characterized 
by a high decentralization and lack of coordination. Decisions at national level 
were based on effectiveness and safety but no clear recommendations were made. 
Therefore we used data from two regional Governments (Andalucía and Cataluña) 
and a pharmacy scientific society (SEFH) where recommendations were stronger and 
considered cost-effectiveness. For the period of 2011-2014 a total of 43 indications 
were assessed in Cataluña: optimized (86%) exceptional use (14%). ConClusions: 
Due to a relative lack of central coordination, the approach to HTA in Spain leads 
to a less standardized approach for technology assessments of cancer drugs than 
in England. In addition, cost-effectiveness evidence is less frequently generated. 
However, a lower proportion of drugs receive a negative recommendation, which 
may reflect both the lower level of cost-effectiveness scrutiny and a relatively higher 
willingness-to-pay.
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objeCtives: To evaluate whether scores from paper (P) and electronic tablet (E) 
versions of seven PRO measures [SF-36v2 Health Survey (Standard), Bath Ankylosing 
Spondylitis Disease Activity Index, Health Assessment Questionnaire, Dermatology 
Quality of Life Instrument, Patient Global Assessment of Disease Activity, Subject 
Assessment of Pain, and, Fatigue Visual Analogue Scale are equivalent. Methods: 
After establishing that patients interpreted P and E instruments in similar ways 
using cognitive interviews, a crossover study was conducted in 53 patients (34 
women) aged 18-83 years. A three-period design was used, with the first two peri-
ods being E and P in randomised order, the third period being P for all patients. This 
allowed both P-E and P-P reliabilities to be compared. Patients’ opinions on ease of 
use and acceptability of the electronic version were collected. Results: Intraclass 
Correlation Coefficients ranged from 0.75 to 0.97, all above the generally accepted 
threshold of .70. Correlations were in general similar for P-E (mode equivalence) 
and P-P (test-retest reliability for paper|) T-tests revealed no significant mean dif-
ference between P and E scores. Mean score differences between P and E measures 
were small and within an acceptable limit of equivalence. The majority of patients 
reported that the electronic tablet was acceptable (99%), and ‘very easy’ (81.8%) or 
‘quite easy’ (14.3%) to use. Few subjects (5%) reported problems using the tablet. The 
majority of patients (37; 74%) preferred the tablet version to paper, while 12 (24%) 
had no preference, and 1 (2%) preferred paper. ConClusions: Results indicate 
that the PRO scores are equivalent when administered to patients with PsA via 
electronic and paper modes. The tablet versions were easy and acceptable to use, 
and preferred over paper versions. These results support the use of the electronic 
tablet versions of the PRO measures in PsA clinical trials.
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objeCtives: Understanding the meaning of differences in HRQL scores is essential 
in communicating the value of treatment to stakeholders. This study translates 
differences in scores from a widely used HRQL measure, the SF-12v2, into differ-
ences in future medical expenditures across 5 major conditions. Methods: Data 
came from the Medical Expenditures Panel Survey (MEPS; n= 20,624), collected in 
2006/2007. Conditions were identified by associated medical events, disability days 
or self-report. Medical expenditures (MEs) were calculated as the sum of payments 
for prescription medicines, hospital inpatient, emergency room, out-patient and 
office-based provider visits in the 6 months following administration of the SF-12v2. 
We modeled the effect of physical (PCS) and mental (MCS) component summary 
scores on MEs using logit-gamma two-part models that controlled for age, gender, 
marital status, comorbidities count and insurance status. Results: A 5-point lower 
PCS score was associated with a 22% increase in MEs among people with asthma and 
diabetes, 18% increase in migraine, 17% increase in depression and 14% increase in 
arthritis. 5-point lower MCS score was associated with a 9% increase in MEs among 
people with diabetes, 8% increase in migraine, 7% increase in arthritis and asthma 
and 4% in depression. The effect of PCS on MEs decreased with age in arthritis 
(P= 0.0210) and similarly for MCS in depression (P= 0.0365). A 5-point lower PCS was 
associated with a 25% increase in MEs in arthritis at age 45 but a 14% increase at age 
areas of the health care system. A critical appraisal was done covering the public HTA 
reports and the decisions for reimbursement of new therapies. Results: The HTA 
implementation started in 2013, but the first model of a scorecard HTA was abrogated 
in April 2014. From July 2014 the HTA responsibility moved at the National Drugs 
Agency and a new scorecard model was introduced. The Romanian HTA system is a 
quick-HTA based on a scorecard which sums up to 145 points, the criteria being: HAS 
(France) evaluation, NICE/SMC (UK) evaluation, IQWIG/G-BA (Germany) evaluation, the 
number of EU countries with reimbursement, the RWD study and the Budget Impact 
Analysis. There are two thresholds: over 80 points for unconditional reimbursement 
and 60-79 points for conditional reimbursements. By the end of 2014 were evaluated 
174 dossiers, including new INNs, new indications and new fixed dose combination. 
After the appeals done by MAHs, 23 new INNs were unconditionally included in the 
List and 51 INNs scored for conditional reimbursement, waiting for the cost-volume 
contracts to be signed in second semester of 2015. ConClusions: The introduction 
of the scorecard HTA in Romania created the possibility to access for new drugs, in a 
transparent and objective manner, for the first time since 2008. The system does not 
require any cost-effectiveness model and has a predominant budget impact perspec-
tive for unconditional reimbursement, but created the circumstances to access on 
the List using commercial arrangements.
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objeCtives: The Health Information and Quality Authority (HIQA) is a statutory, 
government-funded agency in Ireland which monitors the safety and quality of 
the healthcare and social care systems. HIQA has approximately 210 staff, with 7 
working in HTA. Since 2010 we have completed 7 full HTAs and 25 rapid HTAs in 
addition to 6 national HTA guidelines. This study sought to evaluate the impact 
of a national HTA. Methods: In 2013 the Minister for Health requested that we 
examine the implications of establishing a national public access defibrillation 
(PAD) programme in Ireland to increase survival from out-of-hospital cardiac 
http://www.hiqa.ie/healthcare/health-technology-assessment/assessments/hta-
public-access-defibrillation. We sought to measure impact by analysing activity 
under four headings: internal processes; relevance of activity; value of activity; and 
communication of activity. Semi-structured questionnaires were circulated to key 
stakeholders for feedback. Results: Stakeholders indicated that they were happy 
with the management of the project and their opportunities to input into the HTA. 
The methodology used for the evaluation followed best practice, with the model 
reviewed by an external expert. The HTA was explicitly linked to a decision, and 
was found to strongly influence policy. The HTA took 308 person days to complete 
at an estimated cost of € 172,000. Public consultation resulted in over 100 comments 
from 20 individuals or organisations. The report was downloaded 502 times. There 
was greater activity associated with the public consultation version than with the 
final version. ConClusions: The direct link to a policy decision meant that the 
HTA was likely to have high impact, this was supported by the scientific integrity of 
the report. The cost of producing the HTA compared favourably with, for example, 
NIHR funding for full HTAs in the UK. Where public consultation leads to changes in 
a report, it may be necessary to actively increase awareness of the final publication.
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objeCtives: Health Technology Assessment (HTA) is the basis for drug reim-
bursement in many countries, however, it is not always clear how different factors 
are incorporated and weighted by HTA bodies. This research aims to develop a 
model that identifies the drivers of successful HTA submission in five European 
HTA agencies. Methods: Single drug assessments conducted between January 
2011 and April 2015 were extracted from a database of HTA evaluations. The HTA 
outcome (recommendation for National Institute for Health and Care Excellence 
(NICE), Scottish Medicines Consortium (SMC) and Zorginstituut Nederland (ZIN); 
‘Amélioration du service médical rendu’ (ASMR) for Haute Autorité de Santé (HAS) 
and benefit rating for Gemeinsamer Bundesausschuss (G-BA)) and the clinical, 
economic and societal data underlying the assessment were collected. Factors 
influencing the outcome were determined by univariate and multivariate analy-
ses. Results: In total, 1019 HTAs were identified: 108 for G-BA, 464 for HAS, 68 for 
NICE, 218 for SMC and 69 for ZIN. Each model started with 63 explanatory variables, 
which were then refined by omitting variables that showed many missing values. A 
backward regression model was used to develop the models with the best fit. Models 
were chosen following several tests of goodness of fit: Akaike information criterion 
(AIC), likelihood-ratio, Wald-test and residual chi-square, resulting in country-spe-
cific models that predict factors with the best fit. ConClusions: Univariate and 
multivariate backward regressions were used to develop models for understand-
ing the key drivers of HTA recommendations. In most countries, clinical factors 
appeared to be predictive factors for success. In countries performing economic 
evaluations, mainly economic factors appeared to be predictive factors. Societal 
factors were identified less frequently as predictive factors for recommendation. 
The difference in observations per country was a limitation for this research. Further 
research could expand the time horizon in order to increase the observations.
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